Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Gold Miners ETF (GDX) vs Invesco Ltd. (IVZ) Price & Performance

VanEck Gold Miners ETFTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

VanEck Gold Miners ETF vs Invesco Ltd. — how do they compare? VanEck Gold Miners ETF trades at $89.28 (market cap $25.65B), while Invesco Ltd. trades at $29.51 (market cap $13.28B). The key difference: VanEck Gold Miners ETF is the larger of the two by market cap, and Invesco Ltd. pays a 2.86% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Invesco Ltd. for 77 Days on average.

GDXIVZ
Market Cap
$25.65B$13.28B
Volume
16,534,0463,698,033
52-Week High
$115.84$33.31
52-Week Low
$68.28$22.44
Typical Hold Time
76 Days77 Days
Sector
—Financials
Enterprise Value
—$23.45B
Dividend Yield
—2.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Gold Miners ETF

GDX, the VanEck Gold Miners ETF, trades at $89.28, up 4.47% over 24 hours but remains in a bearish technical trend with key resistance at $89. The fund provides exposure to gold mining equities, though specific financial ratios are not available in the provided data. Recent news highlights institutional selling and comparisons between gold miners and physical gold investments.

The outlook for GDX is mixed, with technical indicators signaling caution but potential for gains if gold prices rise. Risks include sensitivity to gold prices, interest rate changes, and miner operational issues. Opportunities exist if macroeconomic factors boost gold demand, but volatility is a key concern for investors.

Invesco Ltd.

Invesco (IVZ) trades at $29.51, down 3.25% today, with bearish technical signals dominating. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, while Q3 2026 results are pending. Despite negative net income margins in 2025, operating cash flow remains strong at $1.53 billion, and analyst consensus leans toward Hold with a $33.71 price target. Recent news highlights ETF expansions and AUM growth to $2.56 trillion in August 2026.

The outlook is cautious; IVZ faces profitability challenges with negative ROE and net margins, but solid cash flow and analyst buy ratings (42.86%) suggest recovery potential. Risks include earnings volatility and competitive ETF pressures, while institutional sentiment is neutral. The stock's current price near the low end of analyst targets ($28-$41) may appeal to value investors betting on operational improvements.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GDX
43% Buy57% Sell
Avg holding period · 76 Days
IVZ

No sentiment data available yet.

Top news

Latest headlines on both assets

About VanEck Gold Miners ETF

The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.

Read more on GDX →

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →